...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmacogenomics >CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention
【24h】

CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention

机译：CYP2C19引导抗血小板治疗：经皮冠状动脉干预后30天和1年成果的成本效益分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim: Determine whether using CYP2C19 genotype to optimize antiplatelet therapy selection is cost effective over the initial 30 days and 1-year following percutaneous coronary intervention. Materials & methods: A cost-effectiveness analysis compared 30-day and 1-year outcomes and cost across three treatment strategies (universal clopidogrel, universal prasugrel, genotype-guided) in a hypothetical cohort. Results: Base-case scenario results at 30 days indicated that the incremental cost per major cardiovascular or bleeding event avoided for genotype-guided treatment was US$8525 and US$42,198 compared with universal clopidogrel and prasugrel, respectively. Probabilistic sensitivity analysis demonstrated that genotype-guided treatment was cost effective over 30 days and 1 year in 62 and 70% of simulations, respectively. Conclusion: Implementing a CYP2C19 genotype-guided approach to antiplatelet therapy could have a positive economic impact by preventing readmissions following percutaneous coronary intervention.
机译：目的：确定是否使用CYP2C19基因型优化抗血小板治疗选择是在经皮冠状动脉干预后的最初30天和1年后的成本效益。材料和方法：成本效益分析在假设的队列中，在三次治疗策略（通用氯吡格雷，通用普拉什雷，基因型引导）中相比为期30天和1年的结果和成本。结果：基本情况下，30天的结果表明，与通用氯吡格雷和普拉布雷相比，避免了避免对基因型引导治疗的每种主要心血管或出血事件的增量成本为8525美元和42,198美元。概率敏感性分析表明，基因型引导治疗分别在62和70％的模拟中超过30天和1年的成本效果。结论：实施CYP2C19基因型引导方法通过预防经皮冠状动脉介入后的入伍，抗血小板治疗方法可能具有积极的经济影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号